Ducentis Biotherapeutics
2015
FOUNDED
PRIVATE
STATUS
Early Stage VC
LATEST DEAL TYPE
$124K
LATEST DEAL AMOUNT
1
INVESTORS
Description
Developer of novel therapies intended to provide treatment for the inflammation and autoimmune disease. The company's novel therapies modifies the protein in such a way as to achieve the improved performance in the treatment of chronic immune diseases such as arthritis, enabling patients to begin treatment more quickly and result in a higher likelihood of a successful treatment.
Website
Formerly Known As
Tripos Biopharma
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Other Industries
Other Healthcare Services
Primary Office
- 9 Blenheim Lane, Freeland
- Oxfordshire
- Witney OX29 8AW
- England
+44 01993 000000
Request full access to PitchBook
You’re viewing a free company profile from the PitchBook Platform. To explore Ducentis Biotherapeutics’s full profile, request a free trial.
Ducentis Biotherapeutics Valuation and Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 1. Early Stage VC | 13-Jul-2015 | $124K | 00000 | Completed | Startup |
Ducentis Biotherapeutics Investors (1)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Board Seat |
Contact Info |
|---|---|---|---|---|---|---|
| Oxford Technology | Venture Capital | Minority | 000 0000 | 000000 0 |
Ducentis Biotherapeutics Executive Team (3)
| Name | Title | Board Seat |
Contact Info |
|---|---|---|---|
| David Blackbourn | Co-Founder, Director & Shareholder | ||
| Philip Huxley Ph.D | Co-Founder & Board Member | ||
| Rebecca Ashfield | Co-Founder & Board Member |
Ducentis Biotherapeutics Board Members (2)
| Name | Representing | Role | Since | Contact Info |
|---|---|---|---|---|
| Philip Huxley Ph.D | Ducentis Biotherapeutics | Co-Founder & Board Member | 000 0000 | |
| Rebecca Ashfield | Ducentis Biotherapeutics | Co-Founder & Board Member | 000 0000 |